Eric Lefkofsky, one of the country’s most influential and successful entrepreneurs is setting his sights on a bold new goal. His latest venture Tempus has dedicated over 100 mllion of dollars toward rolling out a complete solution to advance the research and study of potential cancer treatments. The grand mission of the company is to link cancer treatment facilities across the country in a massive data and research sharing network.
Tempus has developed a completed a working prototype data platform designed around Big Data. Big Data software and concepts may be more commonly applied in other fields, but to date, the medical field does not have nearly the same adoption rate.
Some of the best cancer centers in the country are using complex data models and genetic sequencing to look for patterns. With this data, cancer researchers and physicians hope to better understand the relationship that genetics and treatment have with one another depending on the type of cancer. This process is unfortunately not standard at all cancer centers, and as a result, the entire world misses out on what can be learned from this information.
Tempus seeks to remedy this by bringing a standard data solution industry-wide. The same type of software that analyzes large volumes of molecular and clinical data in high-end cancer centers can be expanded and scaled to fit smaller budgets. As genome sequencing cost continue to decrease, the Tempus platform will become even cheaper to roll out nationwide.
Ultimately, Erik Lefkowsky’s Tempus looks to solve the age-old problem in medicine. Doctors can only know for sure what they have either experienced themselves or have read in a medical journal. By bringing technology on board to automate basic analysis, physicians can spend their time on higher level analysis rather than be hunting for the information they need.
Needless to say, investors are optimistic about Tempus’s potential. With this most recent wave of funding being fully achieved at 70 million dollars, Tempus has now reached $130 million in current venture capital. In addition, Erik Lefkowsky has pledged to invest up to $100 million of his own personal fortune should the company need it.